A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

BeiGene

Status and phase: Completed; Phase 1

Conditions: B-cell Lymphoma

Treatments: Drug: Zanubrutinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT03189524

CTR20160204 (Registry Identifier)

BGB-3111-1002

Details and patient eligibility

About

This phase I clinical study was to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in Chinese participants with B-cell lymphoma by conducting in two stages, the first stage being the safety assessment of dose and the second stage being the dose expansion.

Part I: Safety evaluation - according to the results of preclinical toxicological trials and the results of the phase I clinical study conducted in Australia and New Zealand, two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily [BID]), administered in the morning and at night, or 320 mg once daily [QD]) and "3+3" design was adopted for the assessment. The recommended dose and method of administration of the phase II clinical study was determined according to the Part I results.

Part II: Dose expansion - this stage was to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL), approximately 20 participants with relapsed or refractory FL or MZL were to be enrolled. The recommended Phase 2 dose (RP2D) was used in Part II.

Enrollment: 44 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Men and women between the age of 18-75 years.
• Participants with B-cell lymphoma (defined by World Health Organization classification) refractory or relapsed following at least one line of therapy.
• Judged by the investigator as requiring treatment.
• Eastern Cooperative Oncology Group performance status of 0-1.
• Life expectancy of at least 4 months.
• Adequate hematological function.
• Adequate renal function.
• Adequate liver function.
• Adequate coagulation function.
• Female participants of childbearing potential and non-sterile males must have practiced at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
• Male participants must not have donated sperm from start of study drug administration, until 90 days after discontinuation of treatment.

Key Exclusion Criteria:

• With central nervous system involvement of the disease.
• The pathological type of the disease had disease transformation.
• Had underdone allogeneic hematopoietic stem cell transplantation.
• Had received corticosteroid anti-neoplastic treatment within 7 days before the first dose, has received radiotherapy and chemotherapy within 4 weeks before the first dose or has received treatment with monoclonal antibody within 4 weeks before the first dose.
• Had received BTK inhibitor treatment prior to enrollment.
• Had received chemotherapy and has not yet recovered from toxicity
• Had received Chinese herbal medicine as anti-neoplastic therapy within 4 weeks before starting study treatment.
• History of other malignancies within 2 years before study.
• With uncontrolled systemic infection.
• Major surgery in the past 4 weeks.
• With known HIV, or active hepatitis B or hepatitis C virus infection.
• With cardiovascular disease of New York Heart Association Classification ≥ 3.
• Significant electrocardiogram abnormalities.
• Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participation in the study.
• Inability to comply with study procedures.
• Was currently taking anticoagulant drugs.
• Was currently taking potent cytochrome P450 3A inhibitor or inducer.
• Had stroke or cerebral hemorrhage within 6 months before enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may have applied.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

44 participants in 3 patient groups

Part I: 160 mg BID

Experimental group

Description:

Safety Evaluation: Two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily \[BID\]) administered in the morning and at night, or 320 mg (once daily \[QD\]), and a "3+3" design was adopted for Part I of the study to determine recommended Phase 2 dose (RP2D).

Treatment:

Drug: Zanubrutinib

Part I: 320 mg QD

Experimental group

Description:

Safety Evaluation: Two regimens of zanubrutinib 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and a "3+3" design was adopted for Part I of the study to determine RP2D.

Treatment:

Drug: Zanubrutinib

Part II: 160 mg BID

Experimental group

Description:

Dose Expansion: The RP2D determined in Part I was used in Part II to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Treatment:

Drug: Zanubrutinib